Plant Name: Croton caudatus
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| GPR35; ADRA2C; ADRA2A; | |
| NMUR2; | |
| TDP1; RECQL; BLM; HPGD; AKR1B1; GFER; HSD17B10; ALOX15; USP2; APEX1; POLB; | |
| DUSP3; | |
| GAA; ACHE; | |
| BRAF; FLT4; EPHB4; TEK; PDGFRB; INSR; AKT1; MET; PLK4; MAPK1; ERBB2; EGFR; NUAK1; PLK1; KDR; GSK3B; SRC; IGF1R; MAP3K8; AURKB; AURKA; PTK2; CSNK2A1; | |
| CA2; CA1; CA12; CA9; CA13; CA14; CA5A; CA7; CA4; CA6; | |
| NR1H4; | |
| KDM4E; | |
| BACE1; | |
| FUT7; | |
| SLC22A6; | |
| SMAD3; LMNA; HBB; HSPA1A; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
| Protein Kinase | BRAF | Serine/threonine-protein kinase B-raf | P15056 | CHEMBL5145 |
| Protein Kinase | FLT4 | Vascular endothelial growth factor receptor 3 | P35916 | CHEMBL1955 |
| Protein Kinase | EPHB4 | Ephrin type-B receptor 4 | P54760 | CHEMBL5147 |
| Protein Kinase | TEK | Tyrosine-protein kinase TIE-2 | Q02763 | CHEMBL4128 |
| Protein Kinase | PDGFRB | Platelet-derived growth factor receptor beta | P09619 | CHEMBL1913 |
| Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
| Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | PLK4 | Serine/threonine-protein kinase PLK4 | O00444 | CHEMBL3788 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | ERBB2 | Receptor protein-tyrosine kinase erbB-2 | P04626 | CHEMBL1824 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
| Protein Kinase | PLK1 | Serine/threonine-protein kinase PLK1 | P53350 | CHEMBL3024 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | MAP3K8 | Mitogen-activated protein kinase kinase kinase 8 | P41279 | CHEMBL4899 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | AURKA | Serine/threonine-protein kinase Aurora-A | O14965 | CHEMBL4722 |
| Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Phosphatase | DUSP3 | Dual specificity protein phosphatase 3 | P51452 | CHEMBL2635 |
| SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
| Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Unclassified | SMAD3 | Mothers against decapentaplegic homolog 3 | P84022 | CHEMBL1293258 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | HBB | Hemoglobin beta chain | P68871 | CHEMBL4331 |
| Unclassified | HSPA1A | Heat shock 70 kDa protein 1 | P0DMV8 | CHEMBL5460 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 5.679E-09 | 1.134E-06 | ADRA2A, CA2, CA4, CA9, EGFR, ERBB2, HPGD, SLC22A6, TEK |
| MF | GO:0005488; binding | GO:0019838; growth factor binding | 6.462E-09 | 1.268E-06 | EGFR, ERBB2, FLT4, IGF1R, INSR, KDR, PDGFRB, TEK |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 6.759E-09 | 1.308E-06 | EGFR, IGF1R, INSR, KDR, PTK2, SRC |
| MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 1.047E-08 | 1.869E-06 | EGFR, ERBB2, INSR, KDR |
| MF | GO:0005488; binding | GO:0019901; protein kinase binding | 1.919E-08 | 3.165E-06 | ADRA2A, AKT1, AURKA, BRAF, DUSP3, EGFR, GSK3B, MAPK1, PDGFRB, PLK1, PTK2, SMAD3, SRC |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 2.211E-08 | 3.567E-06 | EGFR, ERBB2, INSR, MET, PDGFRB, PTK2, SRC, TEK |
| BP | GO:0065007; biological regulation | GO:0032148; activation of protein kinase B activity | 6.334E-08 | 9.016E-06 | ADRA2A, ADRA2C, AKT1, INSR, SRC |
| BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 1.650E-07 | 2.139E-05 | ALOX15, BRAF, EGFR, FLT4, KDR, PDGFRB, SRC, TEK |
| BP | GO:0008152; metabolic process | GO:0045429; positive regulation of nitric oxide biosynthetic process | 1.678E-07 | 2.149E-05 | AKT1, EGFR, HBB, INSR, SMAD3 |
| BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 1.041E-06 | 1.084E-04 | AKR1B1, AKT1, APEX1, EGFR, MAPK1, SRC |
| BP | GO:0008152; metabolic process | GO:0043552; positive regulation of phosphatidylinositol 3-kinase activity | 2.170E-06 | 2.119E-04 | PDGFRB, PTK2, SRC, TEK |
| BP | GO:0009987; cellular process | GO:0051495; positive regulation of cytoskeleton organization | 2.357E-06 | 2.251E-04 | ALOX15, BRAF, HSPA1A, MET, PLK4, SMAD3, TEK |
| BP | GO:0009987; cellular process | GO:0035690; cellular response to drug | 2.477E-06 | 2.325E-04 | AKR1B1, APEX1, BLM, BRAF, EGFR, KDR, MAPK1, SRC |
| BP | GO:0032501; multicellular organismal process | GO:0003007; heart morphogenesis | 2.834E-06 | 2.637E-04 | EPHB4, GAA, INSR, PTK2 |
| BP | GO:0051179; localization | GO:1900182; positive regulation of protein localization to nucleus | 3.076E-06 | 2.814E-04 | AKT1, EGFR, MAPK1, PLK1, SMAD3, SRC |
| BP | GO:0050896; response to stimulus | GO:1901653; cellular response to peptide | 3.614E-06 | 3.212E-04 | AKR1B1, AKT1, APEX1, GSK3B, IGF1R, INSR, SRC |
| BP | GO:0008283; cell proliferation | GO:0048661; positive regulation of smooth muscle cell proliferation | 3.806E-06 | 3.356E-04 | AKR1B1, AKT1, EGFR, HPGD, PDGFRB |
| BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 4.061E-06 | 3.551E-04 | ALOX15, EGFR, ERBB2, PDGFRB, SMAD3 |
| MF | Unclassified; | GO:0099600; transmembrane receptor activity | 4.731E-06 | 4.042E-04 | ADRA2A, ADRA2C, EGFR, EPHB4, ERBB2, FLT4, GPR35, HPGD, IGF1R, INSR, KDR, MET, NMUR2, PDGFRB, TEK |
| BP | Unclassified; | GO:0006461; protein complex assembly | 4.762E-06 | 4.050E-04 | ACHE, BLM, BRAF, GSK3B, HBB, HSD17B10, HSPA1A, IGF1R, INSR, PTK2, SLC22A6, SMAD3, SRC, TEK |
| BP | GO:0050896; response to stimulus | GO:0034405; response to fluid shear stress | 5.145E-06 | 4.342E-04 | AKT1, CA2, PDGFRB, SRC |
| BP | GO:0008152; metabolic process | GO:0032436; positive regulation of proteasomal ubiquitin-dependent protein catabolic process | 5.217E-06 | 4.386E-04 | AKT1, AURKA, GSK3B, HSPA1A, PLK1 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 6.194E-06 | 5.129E-04 | BLM, CA1, CA12, CA13, CA2, CA4, CA5A, CA6, CA7, CA9, NR1H4, SMAD3 |
| MF | GO:0003824; catalytic activity | GO:0004712; protein serine/threonine/tyrosine kinase activity | 8.618E-06 | 7.002E-04 | AKT1, AURKA, AURKB, MAPK1 |
| BP | GO:0065007; biological regulation | GO:0043006; activation of phospholipase A2 activity by calcium-mediated signaling | 9.488E-06 | 7.513E-04 | EGFR, NMUR2 |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 9.488E-06 | 7.513E-04 | APEX1, POLB |
| BP | GO:0009987; cellular process | GO:0070507; regulation of microtubule cytoskeleton organization | 9.815E-06 | 7.744E-04 | AURKA, GSK3B, HSPA1A, MET, PLK1, PLK4 |
| BP | GO:0065007; biological regulation | GO:0031647; regulation of protein stability | 1.173E-05 | 9.190E-04 | AURKA, HSPA1A, MAPK1, PLK1, SMAD3, SRC, USP2 |
| BP | GO:0009987; cellular process | GO:0038084; vascular endothelial growth factor signaling pathway | 1.262E-05 | 9.818E-04 | FLT4, KDR, PDGFRB |
| MF | Unclassified; | GO:0004872; receptor activity | 1.430E-05 | 1.085E-03 | ADRA2A, ADRA2C, EGFR, EPHB4, ERBB2, FLT4, GPR35, HPGD, IGF1R, INSR, KDR, MET, NMUR2, NR1H4, PDGFRB, TEK |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 1.480E-05 | 1.119E-03 | ADRA2A, AURKB, CA2, CA7, EGFR, KDR, MAPK1, NR1H4, SRC |
| BP | GO:0009987; cellular process | GO:1901796; regulation of signal transduction by p53 class mediator | 1.750E-05 | 1.300E-03 | AKT1, AURKA, AURKB, BLM, CSNK2A1, NUAK1 |
| BP | GO:0050896; response to stimulus | GO:0042542; response to hydrogen peroxide | 2.129E-05 | 1.545E-03 | AKR1B1, APEX1, HBB, PDGFRB, SRC |
| CC | GO:0043226; organelle | GO:0005876; spindle microtubule | 2.198E-05 | 1.590E-03 | AURKA, AURKB, PLK1, POLB |
| BP | GO:0009987; cellular process | GO:0030168; platelet activation | 2.326E-05 | 1.677E-03 | ADRA2A, ADRA2C, AKT1, MAPK1, SRC |
| CC | GO:0044464; cell part | GO:0048471; perinuclear region of cytoplasm | 2.756E-05 | 1.968E-03 | ACHE, AKR1B1, APEX1, AURKA, CA4, EGFR, ERBB2, HSPA1A, SRC, USP2 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 2.841E-05 | 2.002E-03 | CA2, CA7 |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 2.841E-05 | 2.002E-03 | ADRA2A, ADRA2C |
| MF | GO:0005488; binding | GO:0019903; protein phosphatase binding | 3.263E-05 | 2.256E-03 | AKT1, EGFR, ERBB2, FLT4, MET |
| BP | GO:0008152; metabolic process | GO:2000573; positive regulation of DNA biosynthetic process | 4.649E-05 | 3.040E-03 | AURKB, MAPK1, PDGFRB, SRC |
| BP | GO:0009987; cellular process | GO:0014068; positive regulation of phosphatidylinositol 3-kinase signaling | 5.249E-05 | 3.372E-03 | KDR, PDGFRB, PTK2, TEK |
| MF | GO:0003824; catalytic activity | GO:0046934; phosphatidylinositol-4,5-bisphosphate 3-kinase activity | 5.249E-05 | 3.372E-03 | EGFR, ERBB2, MET, PDGFRB |
| BP | GO:0032501; multicellular organismal process | GO:0030878; thyroid gland development | 5.505E-05 | 3.494E-03 | BRAF, MAPK1, SMAD3 |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 5.670E-05 | 3.528E-03 | ADRA2A, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 5.670E-05 | 3.528E-03 | ADRA2A, ADRA2C |
| CC | GO:0032991; macromolecular complex | GO:0043235; receptor complex | 6.069E-05 | 3.754E-03 | ADRA2A, EGFR, ERBB2, FLT4, IGF1R, INSR, SMAD3 |
| BP | GO:0009987; cellular process | GO:0006974; cellular response to DNA damage stimulus | 6.867E-05 | 4.165E-03 | AKT1, APEX1, AURKA, BLM, MAPK1, NUAK1, PLK1, POLB, RECQL, TDP1 |
| CC | GO:0016020; membrane | GO:0005901; caveola | 6.996E-05 | 4.189E-03 | INSR, MAPK1, SLC22A6, SRC |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 7.093E-05 | 4.197E-03 | AURKB, CA2, CA7, EGFR, MAPK1, NR1H4 |
| BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 7.390E-05 | 4.349E-03 | FLT4, KDR, PTK2, SRC |
| BP | GO:0050896; response to stimulus | GO:0043627; response to estrogen | 7.800E-05 | 4.566E-03 | CA2, MAPK1, PDGFRB, TEK |
| BP | GO:0008152; metabolic process | GO:0006650; glycerophospholipid metabolic process | 7.926E-05 | 4.615E-03 | ACHE, ALOX15, CSNK2A1, EGFR, ERBB2, MET, PDGFRB |
| MF | GO:0003824; catalytic activity | GO:0009378; four-way junction helicase activity | 9.432E-05 | 5.334E-03 | BLM, RECQL |
| CC | GO:0032991; macromolecular complex | GO:0032133; chromosome passenger complex | 9.432E-05 | 5.334E-03 | AURKA, AURKB |
| MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 9.829E-05 | 5.531E-03 | IGF1R, INSR, PDGFRB |
| BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 1.010E-04 | 5.671E-03 | AKT1, CSNK2A1, GSK3B, MAPK1 |
| BP | GO:0032502; developmental process | GO:0051094; positive regulation of developmental process | 1.106E-04 | 6.141E-03 | ADRA2C, AKT1, AURKA, BRAF, CA2, INSR, KDR, LMNA, NR1H4, PDGFRB, SMAD3, SRC, TEK |
| BP | GO:0051179; localization | GO:0051222; positive regulation of protein transport | 1.146E-04 | 6.348E-03 | ACHE, EGFR, ERBB2, GSK3B, MAPK1, NR1H4, SMAD3, SRC |
| BP | GO:0050896; response to stimulus | GO:1901655; cellular response to ketone | 1.170E-04 | 6.469E-03 | AKR1B1, AKT1, EGFR, SRC |
| BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 1.204E-04 | 6.570E-03 | AKT1, EGFR, MAPK1 |
| CC | GO:0043226; organelle | GO:0051233; spindle midzone | 1.204E-04 | 6.570E-03 | AURKA, AURKB, PLK1 |
| MF | GO:0098772; molecular function regulator | GO:0005088; Ras guanyl-nucleotide exchange factor activity | 1.208E-04 | 6.577E-03 | EGFR, ERBB2, MET, PDGFRB, PTK2, TEK |
| BP | GO:0032502; developmental process | GO:0001525; angiogenesis | 1.406E-04 | 7.390E-03 | EPHB4, FLT4, KDR, PDGFRB, PTK2, TEK |
| BP | GO:0008152; metabolic process | GO:2001300; lipoxin metabolic process | 1.412E-04 | 7.390E-03 | ALOX15, HPGD |
| BP | GO:0051179; localization | GO:0051051; negative regulation of transport | 1.415E-04 | 7.390E-03 | ADRA2A, ADRA2C, AKT1, BRAF, GPR35, GSK3B, HSPA1A, NR1H4 |
| MF | GO:0005488; binding | GO:0042562; hormone binding | 1.411E-04 | 7.390E-03 | ACHE, EGFR, IGF1R, INSR |
| MF | GO:0003824; catalytic activity | GO:0035174; histone serine kinase activity | 1.412E-04 | 7.390E-03 | AURKA, AURKB |
| MF | GO:0003824; catalytic activity | GO:0004064; arylesterase activity | 1.412E-04 | 7.390E-03 | CA1, CA2 |
| BP | Unclassified; | GO:0045907; positive regulation of vasoconstriction | 1.455E-04 | 7.524E-03 | ADRA2C, AKT1, EGFR |
| BP | GO:0008283; cell proliferation | GO:0001938; positive regulation of endothelial cell proliferation | 1.477E-04 | 7.584E-03 | AKT1, FLT4, KDR, TEK |
| MF | Unclassified; | GO:0032403; protein complex binding | 1.536E-04 | 7.871E-03 | ACHE, ADRA2A, APEX1, EGFR, IGF1R, INSR, KDR, PLK1, SMAD3, SRC |
| BP | GO:0002376; immune system process | GO:0048534; hematopoietic or lymphoid organ development | 1.692E-04 | 8.589E-03 | BRAF, KDR, MAPK1, POLB, TEK |
| BP | GO:0032501; multicellular organismal process | GO:0007435; salivary gland morphogenesis | 1.973E-04 | 9.697E-03 | EGFR, POLB |
| MF | GO:0060089; molecular transducer activity | GO:0005021; vascular endothelial growth factor-activated receptor activity | 1.973E-04 | 9.697E-03 | FLT4, KDR |
| MF | GO:0098772; molecular function regulator | GO:0030235; nitric-oxide synthase regulator activity | 1.973E-04 | 9.697E-03 | AKT1, EGFR |
| MF | GO:0003824; catalytic activity | GO:0043140; ATP-dependent 3'-5' DNA helicase activity | 1.973E-04 | 9.697E-03 | BLM, RECQL |
| BP | GO:0009987; cellular process | GO:1902905; positive regulation of supramolecular fiber organization | 1.995E-04 | 9.776E-03 | ALOX15, BRAF, HSPA1A, MET, SMAD3 |
| MF | GO:0005488; binding | GO:0044877; macromolecular complex binding | 2.061E-04 | 9.996E-03 | ACHE, ADRA2A, APEX1, CSNK2A1, EGFR, IGF1R, INSR, KDR, PLK1, SMAD3, SRC |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.126E-22 | 2.451E-18 | CA1, CA12, CA13, CA14, CA2, CA4, CA5A, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 6.975E-19 | 3.267E-15 | CA1, CA12, CA13, CA14, CA2, CA4, CA5A, CA6, CA7, CA9, HBB |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.268E-15 | 2.509E-12 | CA1, CA12, CA13, CA2, CA4, CA5A, CA6, CA7, CA9 |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 4.136E-14 | 5.629E-11 | AKT1, AURKA, AURKB, BLM, BRAF, CSNK2A1, EGFR, EPHB4, ERBB2, FLT4, GSK3B, HSPA1A, IGF1R, INSR, KDR, MAP3K8, MAPK1, MET, NUAK1, PDGFRB, PLK1, PLK4, PTK2, RECQL, SRC, TEK |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 5.125E-22 | 7.944E-20 | CA12; CA1; CA2; CA5A; CA4; CA7; CA6; CA9; CA14; CA13 |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 2.629E-14 | 2.038E-12 | PDGFRB; GSK3B; SRC; FLT4; BRAF; PTK2; EGFR; IGF1R; ERBB2; KDR; AKT1; MAPK1; MET |
| hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 1.246E-12 | 4.829E-11 | PDGFRB; SRC; INSR; FLT4; KDR; AKT1; MAPK1; BRAF; TEK; MET; EGFR; IGF1R |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 9.990E-13 | 4.829E-11 | SMAD3; CSNK2A1; SRC; INSR; ERBB2; MAPK1; MET; EGFR; IGF1R |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 3.344E-10 | 6.479E-09 | PDGFRB; GSK3B; INSR; FLT4; KDR; AKT1; MAPK1; TEK; MET; PTK2; EGFR; IGF1R |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 2.363E-10 | 5.231E-09 | PDGFRB; GSK3B; ERBB2; AKT1; MAPK1; BRAF; EGFR; IGF1R |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 1.964E-10 | 5.231E-09 | GSK3B; SRC; ERBB2; AKT1; MAPK1; BRAF; EGFR; PTK2 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 4.507E-10 | 7.762E-09 | SRC; ERBB2; KDR; AKT1; MAPK1; BRAF; MET; PTK2; EGFR; IGF1R |
| hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 2.147E-10 | 5.231E-09 | PLK4; SMAD3; INSR; PLK1; AKT1; MAPK1; BRAF; EGFR; IGF1R |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 1.336E-09 | 2.071E-08 | PDGFRB; INSR; FLT4; KDR; AKT1; MAPK1; TEK; MET; EGFR; IGF1R |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 1.745E-09 | 2.459E-08 | PDGFRB; AKT1; MAPK1; BRAF; MET; EGFR; IGF1R |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 2.352E-08 | 2.672E-07 | PDGFRB; GSK3B; SMAD3; ERBB2; AKT1; MAPK1; BRAF; MET; EGFR; PTK2; IGF1R |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 1.031E-08 | 1.332E-07 | GSK3B; ERBB2; AKT1; MAPK1; BRAF; EGFR |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 4.061E-08 | 4.196E-07 | PDGFRB; AKT1; MAPK1; BRAF; EGFR; IGF1R |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 2.413E-08 | 2.672E-07 | INSR; ERBB2; AKT1; MAPK1; TEK; EGFR; IGF1R |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 4.456E-08 | 4.317E-07 | SMAD3; ERBB2; AKT1; MAPK1; BRAF; EGFR |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 4.883E-08 | 4.453E-07 | PDGFRB; ERBB2; AKT1; MAPK1; MET; EGFR |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 9.032E-07 | 7.000E-06 | PDGFRB; DUSP3; AKT1; MAPK1; BRAF; MAP3K8; EGFR; HSPA1A |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 6.963E-07 | 5.680E-06 | ERBB2; AKT1; MAPK1; BRAF; EGFR |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 1.072E-06 | 7.913E-06 | SRC; KDR; AKT1; MAPK1; PTK2 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 1.414E-07 | 1.217E-06 | SRC; ERBB2; MAPK1; BRAF; EGFR |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.163E-06 | 8.197E-06 | GSK3B; SMAD3; AKT1; MAPK1; BRAF |
| hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 1.211E-05 | 7.511E-05 | SMAD3; SRC; KDR; MET; EGFR; HSPA1A; IGF1R |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 1.124E-05 | 7.511E-05 | PLK1; AKT1; MAPK1; BRAF; IGF1R |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 1.181E-05 | 7.511E-05 | SRC; AKT1; MAPK1; EGFR; HSPA1A |
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 2.030E-05 | 1.210E-04 | GSK3B; SRC; AKT1; MAPK1; BRAF; PTK2 |
| hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 4.327E-05 | 2.313E-04 | PDGFRB; SRC; MAPK1; BRAF; PTK2; EGFR |
| hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 3.939E-05 | 2.250E-04 | GSK3B; MAPK1; MET; PTK2; EPHB4 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 4.912E-05 | 2.456E-04 | GSK3B; AKT1; MAPK1; BRAF; EGFR |
| hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 4.064E-05 | 2.250E-04 | INSR; AKT1; HSPA1A; IGF1R |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 6.061E-05 | 2.936E-04 | GSK3B; INSR; AKT1; MAPK1; BRAF |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 6.708E-05 | 3.022E-04 | GSK3B; SMAD3; AKT1; MAPK1; IGF1R |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 7.168E-05 | 3.086E-04 | PDGFRB; INSR; AKT1; MAPK1; EGFR |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 4.590E-05 | 2.371E-04 | AKT1; MAPK1; BRAF; MET |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 1.441E-04 | 5.877E-04 | INSR; AKT1; MAPK1; ADRA2C; ADRA2A |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 6.464E-05 | 3.022E-04 | GSK3B; SRC; AKT1; MAPK1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 6.824E-05 | 3.022E-04 | SMAD3; AKT1; MAPK1; BRAF |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 2.405E-04 | 9.557E-04 | PDGFRB; AKT1; MAPK1; EGFR |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 2.690E-04 | 1.042E-03 | GSK3B; AKT1; MAPK1; MAP3K8 |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 1.414E-04 | 5.877E-04 | PDGFRB; SRC; MAPK1; EGFR |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 4.637E-04 | 1.711E-03 | GSK3B; AKT1; MAPK1; BRAF |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 4.351E-04 | 1.645E-03 | GSK3B; SRC; AKT1; MAPK1 |
| hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 5.091E-04 | 1.835E-03 | PLK1; MAPK1; AURKA; IGF1R |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 7.427E-04 | 2.558E-03 | GSK3B; CSNK2A1; AKT1; HSPA1A |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 9.677E-04 | 3.125E-03 | SMAD3; SRC; AKT1; MAPK1 |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 1.053E-03 | 3.329E-03 | PDGFRB; POLB; GSK3B; SMAD3; AKT1 |
| hsa04060 | Cytokine-cytokine receptor interaction_Homo sapiens_hsa04060 | 1.185E-03 | 3.603E-03 | PDGFRB; FLT4; KDR; MET; EGFR |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.957E-03 | 5.417E-03 | PDGFRB; ERBB2; MAPK1; MET; EGFR |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 1.886E-03 | 5.314E-03 | GSK3B; AKT1; MAPK1; HSPA1A |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.624E-03 | 4.751E-03 | BACE1; GSK3B; MAPK1; HSD17B10 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 2.089E-03 | 5.682E-03 | HPGD; MET; PTK2; IGF1R |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 3.168E-03 | 7.919E-03 | GSK3B; CSNK2A1; AKT1; HSPA1A |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 6.693E-04 | 2.358E-03 | AKT1; MAPK1; BRAF |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 1.375E-03 | 4.099E-03 | GSK3B; AKT1; MAPK1 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 7.778E-04 | 2.565E-03 | AKT1; MAPK1; BRAF |
| hsa04730 | Long-term depression_Homo sapiens_hsa04730 | 7.778E-04 | 2.565E-03 | MAPK1; BRAF; IGF1R |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 3.472E-03 | 8.409E-03 | SMAD3; AKT1; MAPK1 |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 2.585E-03 | 6.792E-03 | SRC; MAPK1; EGFR |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 2.835E-03 | 7.322E-03 | INSR; AKT1; IGF1R |
| hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 1.120E-03 | 3.472E-03 | SRC; MET; EGFR |
| hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 1.664E-03 | 4.777E-03 | SRC; MET; PTK2 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 3.977E-03 | 9.201E-03 | AKT1; MAPK1; MAP3K8 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 4.300E-03 | 9.769E-03 | GSK3B; INSR; AKT1 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 3.770E-03 | 8.854E-03 | SMAD3; AKT1; MAPK1 |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 4.525E-03 | 9.878E-03 | ACHE; AKT1; MAPK1 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 4.412E-03 | 9.769E-03 | AKT1; MAPK1; MAP3K8 |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 5.884E-03 | 1.216E-02 | SRC; AKT1; MAPK1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 8.588E-03 | 1.664E-02 | LMNA; AKT1; MAPK1 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 4.639E-03 | 9.988E-03 | ALOX15; MAPK1; BRAF |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 9.566E-03 | 1.765E-02 | GPR35; NMUR2; ADRA2C; ADRA2A |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 5.365E-03 | 1.124E-02 | AKT1; MAPK1; HSPA1A |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 8.926E-03 | 1.708E-02 | GSK3B; SMAD3; CSNK2A1 |
| hsa04530 | Tight junction_Homo sapiens_hsa04530 | 8.421E-03 | 1.652E-02 | CSNK2A1; SRC; AKT1 |
| hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 6.155E-03 | 1.223E-02 | INSR; AKT1; IGF1R |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 6.155E-03 | 1.223E-02 | GSK3B; SMAD3; PLK1 |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 1.054E-02 | 1.901E-02 | GSK3B; INSR; AKT1 |
| hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 1.191E-02 | 2.123E-02 | SRC; MAPK1; EGFR |
| hsa04020 | Calcium signaling pathway_Homo sapiens_hsa04020 | 1.686E-02 | 2.841E-02 | PDGFRB; ERBB2; EGFR |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 1.637E-02 | 2.819E-02 | SRC; AKT1; MAPK1 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 2.368E-02 | 3.824E-02 | POLB; SRC; MAPK1 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 2.193E-02 | 3.578E-02 | AKT1; MAPK1; BRAF |
| hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 3.180E-02 | 4.979E-02 | AKT1; MAPK1 |
| hsa04350 | TGF-beta signaling pathway_Homo sapiens_hsa04350 | 2.636E-02 | 4.212E-02 | SMAD3; MAPK1 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 2.753E-02 | 4.355E-02 | AKT1; PTK2 |
| hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 1.776E-02 | 2.960E-02 | AKT1; MAPK1 |
| hsa04720 | Long-term potentiation_Homo sapiens_hsa04720 | 1.679E-02 | 2.841E-02 | MAPK1; BRAF |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.926E-02 | 3.176E-02 | CA2; NR1H4 |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 1.631E-02 | 2.819E-02 | SRC; MAPK1 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.228E-02 | 2.164E-02 | INSR; AKT1 |
| hsa05144 | Malaria_Homo sapiens_hsa05144 | 9.507E-03 | 1.765E-02 | HBB; MET |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 9.884E-03 | 1.802E-02 | INSR; IGF1R |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 9.137E-03 | 1.727E-02 | INSR; MAPK1 |
| hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 6.107E-03 | 1.223E-02 | INSR; MAPK1 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 3.411E-03 | 8.392E-03 | MAPK1; BRAF |
| hsa04320 | Dorso-ventral axis formation_Homo sapiens_hsa04320 | 2.960E-03 | 7.522E-03 | MAPK1; EGFR |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 3.647E-03 | 8.698E-03 | GAA; AKR1B1 |
| hsa05020 | Prion diseases_Homo sapiens_hsa05020 | 4.941E-03 | 1.049E-02 | MAPK1; HSPA1A |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 4.402E-03 | 9.769E-03 | POLB; APEX1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 2.150E-03 | 5.746E-03 | CA2; CA4 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; EGFR |
| H00-H59: Diseases of the eye and adnexa | Retinal venous occlusion | H34.8 | ERBB2 |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; KDR; KDR; KDR; EGFR; EGFR |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; ACHE; CA4 |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | ADRA2C |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; KDR; ERBB2; EGFR; EGFR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | FLT4; MET; KDR; IGF1R |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vascular restinosis following vascular graft surgery | T82.858A | FLT4 |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PDGFRB; MET; KDR; EGFR; EGFR; IGF1R; IGF1R |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | ERBB2; PLK1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | INSR |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PDGFRB; INSR; AKR1B1; GSK3B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | ADRA2C |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TEK; KDR |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | FLT4; TEK; PDGFRB; AURKA; AKT1; MET; KDR; KDR; KDR; SRC; CA9; MAPK1; ERBB2; EGFR; PLK1; PLK1; IGF1R; PTK2; AURKB |
| C00-D49: Neoplasms | Solid tumors | NA | BRAF |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C; CA4; CA4 |
| K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKA; PLK1; AURKB |
| C00-D49: Neoplasms | Cancer | C00-C96 | FLT4; EPHB4; TEK; AURKA; AKT1; MET; CA1; KDR; SRC; CA9; MAPK1; ERBB2; ERBB2; EGFR; PLK1; ACHE; GSK3B; IGF1R; PTK2; BRAF; BRAF; CSNK2A1 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; BRAF |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ADRA2C; ACHE |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; ERBB2 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; AKR1B1; ADRA2C; ACHE |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; KDR; EGFR; PLK1 |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
| C00-D49: Neoplasms | Bladder cancer | C67 | ERBB2; EGFR |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Beta thalassemia | D56.1 | HBB |
| C00-D49: Neoplasms | Haematological malignancies | C81-C86 | AURKA |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
| NA: NA | Edema | NA | CA2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | TEK |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | PDGFRB |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | SRC; EGFR; EGFR |
| C00-D49: Neoplasms | Breast cancer | C50 | INSR; KDR; KDR; KDR; CA9; ERBB2; ERBB2; ERBB2; EGFR; EGFR; EGFR; IGF1R |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADRA2C |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; KDR; EGFR; EGFR; EGFR; AKR1B1 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | ERBB2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SRC; AURKB |
| C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; CA9 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | EGFR |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT4; ERBB2; EGFR; PLK1 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | INSR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | TEK; SRC |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR |
| C00-D49: Neoplasms | Colon cancer | C50 | EGFR |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | KDR; ERBB2; EGFR; EGFR; IGF1R |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; KDR |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | FLT4; EGFR |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | AKT1; INSR; CA9; ERBB2; EGFR; PLK1 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | AURKA; PTK2; BRAF |
| C00-D49: Neoplasms | Late-stage non-small cell lung cancer | C33-C34 | EPHB4 |
| C00-D49: Neoplasms | Liver cancer | C22 | KDR; IGF1R |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | INSR; ADRA2C; ACHE; ACHE; ACHE; GSK3B |
| C00-D49: Neoplasms | AML | NA | KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | INSR |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; KDR; EGFR; BRAF |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2C |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | AURKA; MET; PLK1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ERBB2; ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC; ERBB2; EGFR; EGFR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
| C00-D49: Neoplasms | Metastatic melanoma | C43 | BRAF; BRAF |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR |
| C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | INSR |
| C00-D49: Neoplasms | HER2-positive urogenital cancer | NA | ERBB2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; GSK3B |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
| C00-D49: Neoplasms | Multiple myeloma | C90 | SRC; IGF1R |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
| C00-D49: Neoplasms | Glioma | C71 | KDR; EGFR; EGFR |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; BRAF |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | INSR; ADRA2C; ADRA2A; ACHE; IGF1R |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |